Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Nyxoah S.A. specializes in innovative solutions for obstructive sleep apnea (OSA), primarily through its proprietary Genio system, which offers a unique neurostimulation therapy. The company operates in the global healthcare market, focusing on regions with high prevalence of OSA, such as North America and Europe, and is positioned to capitalize on the growing demand for non-invasive treatment options.
Nyxoah generates revenue by selling its Genio neurostimulation devices to hospitals and clinics, which are then used to treat patients with OSA. The company benefits from a high gross margin of 63.1%, indicating strong pricing power and demand for its innovative therapy. The competitive advantage lies in its unique technology that offers a less invasive alternative to traditional CPAP machines.
Regulatory approvals for new markets or indications
Partnerships with healthcare providers for distribution
Clinical trial results demonstrating efficacy and safety
Market adoption rates of the Genio system
Regulatory changes impacting medical device approvals
Technological disruption from new treatment modalities
Emergence of alternative therapies for OSA
Increased competition from established medical device companies
High operating losses leading to liquidity concerns
Debt levels approaching 1.01 debt/equity ratio may limit financial flexibility
moderate - The demand for healthcare products can be somewhat insulated from economic cycles, but overall consumer spending and healthcare budgets may influence sales.
Interest rates affect Nyxoah's cost of capital and financing for R&D, which could impact growth initiatives and valuations.
minimal - The company does not rely heavily on credit for operations, but higher interest rates could affect future financing options.
growth - Investors are likely attracted to Nyxoah for its potential in a growing healthcare niche and innovative product offering.
high - The stock has exhibited significant volatility with a 1-year return of -79.1%, indicating high risk.